SCHEMBL2200138

SCHEMBL2200138

Cc1cc(Br)ccc1Nc1ccc(C(=O)c2cc(C(=O)O)ccc2C)c(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 10/20 0.60
MAPK12 P53778 10/20 0.60
MAPK11 Q15759 10/20 0.60
MAPK14 Q16539 10/20 0.60
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
AKR1C3 P42330 4/20 0.46
AKR1C2 P52895 4/20 0.46
RPA1 P27694 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 2/20 0.42
BCL6 P41182 1/20 0.40
BCOR Q6W2J9 1/20 0.40
AKR1B10 O60218 1/20 0.40
AKR1B1 P15121 1/20 0.40
AKR1C4 P17516 1/20 0.40
AKR1C1 Q04828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2200460 0.89 MAPK14 (0.58) MAPK13MAPK12MAPK11MAPK14AKR1C3
SCHEMBL5174760 0.88 MAPK13 (0.63) MAPK13MAPK12MAPK11MAPK14ALDH1A1
SCHEMBL2197489 0.87 KMT2A (0.60) MAPK13MAPK12MAPK11MAPK14ALDH1A1
SCHEMBL2201071 0.85 MAPK13 (0.53) MAPK13MAPK12MAPK11MAPK14AKR1C3
SCHEMBL1906530 0.84 MAPK14 (0.81) MAPK13MAPK12MAPK11MAPK14ALDH1A1
SCHEMBL1906099 0.84 MAPK13 (0.64) MAPK13MAPK12MAPK11MAPK14AKR1C3
SCHEMBL2199211 0.83 MAPK13 (0.63) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL1904469 0.82 MAPK13 (0.76) MAPK13MAPK12MAPK11MAPK14ALDH1A1
SCHEMBL2200872 0.82 MAPK14 (0.62) MAPK13MAPK12MAPK11MAPK14MAPT
SCHEMBL2197804 0.82 MAPK13 (0.53) MAPK13MAPK12MAPK11MAPK14KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006528597-A 2006-12-21 JP claimed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US claimed
EP-1658263-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS Leo Pharma A/S (DK) 2006-05-24 EP claimed
WO-2005009940-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA A/S (DK) 2005-02-03 WO claimed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US disclosed
EP-1658263-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS Leo Pharma A/S (DK) 2006-05-24 EP disclosed
WO-2005009940-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA A/S (DK) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166990-A1 Novel aminobenzophenone compounds NFKBIA, UACA, ALDH7A1 MAPK13 1063/4885MAPK12 955/4885MAPK11 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.